Libranza, Susa O.
HRN: 23-84-19 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/04/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/04/2023
10/11/2023
IV
500mg
TID
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes